Deutsche Bank Downgrades Argenx SE (ARGX) to Hold From Buy

Argenx SE (NASDAQ:ARGX) is one of the top high growth international stocks to buy right now. On September 11, Deutsche Bank downgraded Argenx SE (NASDAQ:ARGX) to Hold from Buy, keeping the price target unchanged at EUR 655.

Is argenx SE (ARGX) the Best Cancer Stock to Invest in for Long-Term Gain?

The firm noted that the stock price shot up more than 40% since its pre-Q2 upgrade two months ago, stating that it is attempting to be “reasonably disciplined” with its valuation and price target framework.

Headquartered in Amsterdam, the Netherlands, Argenx SE (NASDAQ:ARGX) is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.

While we acknowledge the potential of ARGX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARGX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.